Neuropsychologists are essential in decoding the behavioral and cognitive impact of neurological disorders. Their work involves detailed assessments that map brain function to specific cognitive processes such as memory, attention, language, and executive control. These evaluations guide diagnosis and treatment in conditions like stroke, traumatic brain injury, Alzheimer’s disease, and epilepsy. By using standardized tools and performance metrics, neuropsychologists help distinguish between psychiatric, developmental, and organic brain disorders. Their insights also inform rehabilitation strategies, helping clinicians tailor cognitive-behavioral interventions to an individual’s strengths and limitations. Neuropsychologists often work within multidisciplinary teams in hospitals, rehabilitation centers, and academic settings. They also contribute significantly to pre-surgical planning, especially in epilepsy and tumor resections, by identifying eloquent brain regions critical to function. As digital technologies evolve, neuropsychologists are embracing remote assessments, computerized testing platforms, and AI-enhanced scoring to increase accessibility and accuracy. Their research advances understanding of how aging, disease, and injury affect cognition across the lifespan. In pediatric contexts, neuropsychologists play a critical role in developmental assessment, differentiating between learning disabilities and neurodevelopmental disorders. Ultimately, neuropsychologists serve as translators between brain changes and behavioral symptoms, offering a nuanced understanding that informs both diagnosis and care. Their role is growing more essential as cognitive health becomes central to neurological care.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States